share_log

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca將在古根海姆證券中型市值生物技術會議上發佈演講
GlobeNewswire ·  01/31 13:00

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings.

聖地亞哥,2025年1月31日(全球新聞通訊)-- Erasca公司(納斯達克:ERAS),一家臨牀階段的精準腫瘤學公司,專注於發現、開發和商業化針對RAS/MAPK信號通路驅動的癌症患者的療法,今天宣佈將參加在紐約大樓的樂天紐約宮舉行的古根海姆證券中小型生物科技會議。管理層將在2025年2月6日東部時間上午9:30參加一個爐邊聊天,並將參與一對一的投資者會議。

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

該活動的現場音頻網絡廣播將在線上通過Erasca.com/events提供。活動的錄播將在網絡廣播後30天內可在Erasca.com/events訪問。

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry. We believe our team's capabilities and experience, further guided by our scientific advisory board which includes the world's leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

關於Erasca
在Erasca,我們的名字就是我們的使命:消除癌症。我們是一家臨牀階段的精準腫瘤學公司,專注於發現、開發和商業化針對RAS/MAPk通路驅動癌症患者的療法。我們的公司由精準腫瘤學和RAS靶向治療領域的領先先鋒共同創立,旨在創造新型療法和組合方案,全面關閉RAS/MAPk通路以治療癌症患者。我們已彙集了行業中目前最全面的專注於RAS/MAPk通路的管道之一。我們相信,我們團隊的能力和經驗,加上包括全球領先的RAS/MAPk通路專家在內的科學諮詢委員會的指導,獨特地使我們能夠實現消除癌症的宏偉使命。

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

聯繫:
喬伊斯·阿拉爾
生命科學顧問公司
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

來源:Erasca公司。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 351

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。